Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 3
2017 4
2018 4
2019 4
2020 2
2021 5
2022 6
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmström MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. Kjeldsen JW, et al. Among authors: martinenaite e. Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9. Nat Med. 2021. PMID: 34887574 Free PMC article. Clinical Trial.
TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M, Weis-Banke SE, Schina A, Siersbæk M, Hübbe ML, Jørgensen MA, Lecoq I, Lara de la Torre L, Bendtsen SK, Martinenaite E, Holmström MO, Madsen DH, Donia M, Ødum N, Grøntved L, Andersen MH. Perez-Penco M, et al. Among authors: martinenaite e. J Immunother Cancer. 2022 Dec;10(12):e005491. doi: 10.1136/jitc-2022-005491. J Immunother Cancer. 2022. PMID: 36600556 Free PMC article.
Frequent adaptive immune responses against arginase-1.
Martinenaite E, Mortensen REJ, Hansen M, Orebo Holmström M, Munir Ahmad S, Grønne Dahlager Jørgensen N, Met Ö, Donia M, Svane IM, Andersen MH. Martinenaite E, et al. Oncoimmunology. 2017 Dec 26;7(3):e1404215. doi: 10.1080/2162402X.2017.1404215. eCollection 2018. Oncoimmunology. 2017. PMID: 29399404 Free PMC article.
Peripheral memory T cells specific for Arginase-1.
Martinenaite E, Ahmad SM, Svane IM, Andersen MH. Martinenaite E, et al. Cell Mol Immunol. 2019 Aug;16(8):718-719. doi: 10.1038/s41423-019-0231-3. Epub 2019 May 10. Cell Mol Immunol. 2019. PMID: 31076727 Free PMC article. No abstract available.
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.
Klausen U, Grauslund JH, Jørgensen NGD, Ahmad SM, Jonassen M, Weis-Banke SE, Martinenaite E, Pedersen LB, Lisle TL, Gang AO, Enggaard L, Hansen M, Holmström MO, Met Ö, Svane IM, Niemann CU, Pedersen LM, Andersen MH. Klausen U, et al. Among authors: martinenaite e. Front Oncol. 2022 Nov 22;12:1023015. doi: 10.3389/fonc.2022.1023015. eCollection 2022. Front Oncol. 2022. PMID: 36483037 Free PMC article.
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment.
Bendtsen SK, Perez-Penco M, Hübbe ML, Martinenaite E, Orebo Holmström M, Weis-Banke SE, Grønne Dahlager Jørgensen N, Jørgensen MA, Munir Ahmad S, Jensen KM, Friese C, Lundsager MT, Johansen AZ, Carretta M, Ødum N, Met Ö, Svane IM, Madsen DH, Andersen MH. Bendtsen SK, et al. Among authors: martinenaite e. Oncoimmunology. 2022 Jan 27;11(1):2026020. doi: 10.1080/2162402X.2022.2026020. eCollection 2022. Oncoimmunology. 2022. PMID: 35111385 Free PMC article.
29 results